Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR)

Abstract

During this funding period we have shown that inhibition of the type 1 IGF receptor with a fully human monoclonal antibody can delay prostate cancer growth in intact and castrate human xenograft mouse models. Further IGF-IR inhibition of IGF-IR greatly enhanced the effects of castration and docetaxel on prostate cancer. There was a significant effect on prostate cancer when growing in bone, especially in combination with Docetaxel. There was no evidence of significant treatment toxicity. The results of these preclinical studies have led to phase 1 and 2 clinical trials in each instance.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2009
Accession Number
ADA524529

Entities

People

  • Stephen R Plymate

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Body Weight
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Databases
  • Dna Microarrays
  • Gene Expression
  • Health Services
  • Neoplasms
  • Peptide Growth Factors
  • Prostate Cancer
  • Proteins

Fields of Study

  • Biology
  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology (Cancer Research).